Effect of malignancy on semen quality in men undergoing fertility preservation prior to cancer treatment

Deepthi Leelia Betzy R.; Kundavi Shankar; Geetha Veerasigamani; Yamini Asokan; Rashmi Gingade Vittal; Geovin Ranji G.; Hema Niveda K. R.; Sandhya Devarajan

doi:10.18203/2320-1770.ijrcog20261628

Authors

Deepthi Leelia Betzy R. Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Kundavi Shankar Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Geetha Veerasigamani Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Yamini Asokan Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Rashmi Gingade Vittal Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Geovin Ranji G. Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Hema Niveda K. R. Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India
Sandhya Devarajan Institute of Reproductive Medicine, The Madras Medical Mission, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261628

Keywords:

Cancer, Male fertility, Sperm cryopreservation, Semen analysis, Testicular malignancy

Abstract

Background: Advances in cancer therapy have significantly improved survival rates, making fertility preservation an essential component of cancer care in young men. While gonadotoxic effects of chemotherapy and radiotherapy are well established, the impact of malignancy itself on semen parameters prior to treatment remains controversial. To evaluate semen parameters in men with various malignancies prior to chemotherapy or radiotherapy and to compare semen quality between testicular and non-testicular cancers.

Methods: This single-center retrospective study included 130 male cancer patients referred for sperm cryopreservation between January 2015 and December 2024. Patients who had received prior chemotherapy or radiotherapy were excluded. Semen samples obtained before initiation of cancer treatment were analyzed for sperm concentration, total motility and progressive motility according to World Health Organization (WHO) criteria, 6th edition 2021. Semen parameters were compared across different malignancy types, including testicular and non-testicular cancers.

Results: The mean age was 25.25 years. Out of 130 patients, 104 patients (80%) had abnormal morphology. Normozoospermia was observed in 13.07% of patients, while 86.9% had at least one semen abnormality. Testicular malignancies were associated with a significantly higher proportion of subnormal sperm concentration (<16 million/ml) compared to non-testicular cancers (58.1% vs. 35.6%, p=0.015). Total sperm motility showed a significant association with cancer type (p=0.034), with hematological and musculoskeletal malignancies demonstrating higher rates of reduced motility. Progressive motility did not differ significantly between testicular and non-testicular cancers.

Conclusions: A substantial proportion of men with cancer exhibit impaired semen parameters even before initiation of gonadotoxic therapy. Testicular malignancy is significantly associated with reduced sperm concentration, while systemic malignancies may adversely affect sperm motility. Early referral for fertility preservation should be strongly recommended for all reproductive-age men diagnosed with cancer.

References

Romero Meistrich ML. Effects of cancer treatment on male fertility. Fertil Steril. 2013;100(5):1180-6.

Howell SJ, Shalet SM. Effect of cancer therapy on the pituitary-testicular axis. Int J Androl. 2002;25(5):269-76.

Van Casteren NJ, Boellaard WP, Dohle GR, Weber RF. Fertility preservation in men with cancer. Hum Reprod Update. 2008;14(5):487-99.

Oldereid NB, Hanevik HI, Bakkevig I. Fertility preservation and reproduction in cancer patients. Fertil Steril. 2018;109(3):422-8.

Williams DH 4th, Karpman E, Sander JC, Spiess PE, Pisters LL, Lipshultz LI. Pretreatment semen parameters in men with cancer. J Urol. 2009;181(2):736-40.

Ku JY, Park NC, Jeon TG, Park HJ. Semen analysis in cancer patients referred for sperm cryopreservation before chemotherapy over a 15-year period in Korea. World J Men Health. 2015;33(1):8-13.

Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. Lancet Oncol. 2003;4(10):589-95.

Huszar G, Patrizio P, Veeck L, Willets M, Wilker C. Spermatogenic impairment in testicular cancer: mechanisms and clinical implications. Andrology. 2020;8(5):1156-65.

Fossa SD, Dahl AA, Loge JH. Male fertility after cancer: risks and preservation strategies. Nat Rev Urol. 2019;16(9):555-66.

Chung K, Irani J, Knee G, Efymow B, Blasco L, Patrizio P. Sperm cryopreservation for male patients with cancer: an epidemiological analysis at the University of Pennsylvania. Eur J Obstet Gynecol Reprod Biol. 2004;113:7.

Ragni G, Somigliana E, Restelli L, Salvi R, Arnoldi M, Paffoni A. Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients. Cancer. 2003;97:1624.

Gandini L, Lombardo F, Paoli D, Caruso F, Eleuteri P, Leter G, et al. Sperm DNA fragmentation in cancer patients before treatment. Hum Reprod. 2000;15(6):1318-22.

Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N. Semen quality before and after gonadotoxic treatment. Hum Reprod. 2005;20:774.

Meseguer M, Molina N, Garcia-Velasco JA, Remohi J, Pellicer A, Garrido N. Sperm cryopreservation in oncological patients: a 14-year follow-up study. Fertil Steril. 2006;85:640.

Song SH, Lee TH, Her YS. Semen quality and sperm DNA fragmentation in cancer patients undergoing sperm cryopreservation. Investig Clin Urol. 2023;64(5):489-94.

World Health Organization. WHO laboratory manual for the examination and processing of human semen. 6th ed. Geneva: World Health Organization. 2021.